

Memorandum

Date: January 15, 2014

To: Gian-Carl Casa, Undersecretary for Legislative Affairs, OPM
Liz Donohue, Policy Director, Office of the Governor
Aaron Frankel, Governors Policy Office

From: Lori Granato, Director, Government Affairs, CII



Re: CII Legislative Proposals for the 2014 Legislative Session

Please find enclosed Connecticut Innovations 2014 Legislative Proposals in priority order.

1. **AAC changes to CII pre seed statutes**
2. **AAC changes to CII's Bioscience Innovation Fund**
3. **AAC Changes to Angel Tax Credits**
4. **AAC CHANGES TO CII'S bio facilities fund**

In addition, CII is working on a proposal with Liz Donahue, Jamie Mills et.al. regarding the Stem Cell Bill language and has agreed to fund \$65,000 for the Social Enterprise (Reset) bill.

If you should have questions or require additional information please feel free to contact me at 860.258.7872 or 860.306.9315



Agency Legislative Proposal - 2014 Session

Document Name **AAC changes to CI's Preseed language**

(If submitting an electronically, please label with date, agency, and title of proposal – 092611_SDE_TechRevisions)

State Agency: CONNECTICUT INNOVATIONS, INC

Liaison: Lori Granato

Phone: 860 258 7872 © 860 306 9315

E-mail: Lori.granato@ctinnovations.com

Lead agency division requesting this proposal: Connecticut Innovations

Agency Analyst/Drafter of Proposal: Lori Granato

Title of Proposal **AAC changes to CII Preseed language**

Statutory Reference **32 41(x)**

Proposal Summary

The following is required to ensure that early stage companies that the Corporation feels warrant continued support don't run out of money and/or traction (which could make many of the \$150,000 level first investments unsuccessful). Additionally, many of these companies are at a stage that makes it difficult to attract significant funding or funding in a timely manner. The ability of the Corporation to continue to support these companies is in the best interests of the companies and the Corporation. It allows the potential to leverage the original investments in hopes of raising additional capital, extending time horizons, and making successful companies/investments.

Please attach a copy of fully drafted bill (required for review)

Please consider the following, if applicable:

- (1) Have there been changes in federal/state/local laws and regulations that make this legislation necessary?
- (2) Has this proposal or something similar been implemented in other states? If yes, what is the outcome(s)?
- (3) Have certain constituencies called for this action?
- (4) What would happen if this was not enacted in law this session?



- **Origin of Proposal** ___ New Proposal ___ Resubmission

If this is a resubmission, please share:

- (1) *What was the reason this proposal did not pass, or if applicable, was not included in the Administration's package?*
- (2) *Have there been negotiations/discussions during or after the previous legislative session to improve this proposal?*
- (3) *Who were the major stakeholders/advocates/legislators involved in the previous work on this legislation?*
- (4) *What was the last action taken during the past legislative session?*

PROPOSAL IMPACT

- **Agencies Affected** (please list for each affected agency)

Agency Name:

Agency Contact (name, title, phone):

Date Contacted:

Approve of Proposal ___ YES ___ NO ___ Talks Ongoing

Summary of Affected Agency's Comments

Will there need to be further negotiation? ___ YES ___ NO

- **Fiscal Impact** (please include the proposal section that causes the fiscal impact and the anticipated impact)

Municipal (please include any municipal mandate that can be found within legislation)

State

Federal

Additional notes on fiscal impact



- **Policy and Programmatic Impacts** (Please specify the proposal section associated with the impact)

Insert fully drafted bill here

Sec. 32-41x. Preseed financing account and program. (a) There is established an account to be known as the “preseed financing account” which shall be a separate, nonlapsing account within the General Fund. The account shall contain any moneys required by law to be deposited in the account. Moneys in the account shall be expended by Connecticut Innovations, Incorporated, for the purposes of providing preseed financing pursuant to the program established in subsection (b) of this section.

(b) Connecticut Innovations, Incorporated, shall establish a program to provide preseed financing for Connecticut businesses, which shall include, but not be limited to, financial assistance for the development of proof of concepts and support services. Financial assistance shall not exceed one hundred fifty thousand dollars per eligible business. An eligible business shall (1) **if such business has employees then** not less than seventy-five per cent of its employees working in Connecticut, and (2) demonstrate private investment dollars of not less than fifty cents for every dollar of financial assistance sought from the program established pursuant to this section. For the purposes of this subsection, “private investment dollars” shall include funds from a public institution of higher education, except those funds derived from state appropriations or student tuition and fees, that are used to assist in the commercialization of technology owned by a public university. **The corporation shall have the further authority to provide up to \$200,000 in follow-on funding to a business that was eligible for and received pre-seed funding pursuant to the foregoing provisions of this subsection with a matching requirement set by Board policy with a minimum match of ten per-cent, providing that if such business has employees then seventy-five per cent of its employees shall work in Connecticut.**

(P.A. 10-75, S. 12; P.A. 11-218, S. 1.)

History: P.A. 10-75 effective July 1, 2010; P.A. 11-218 amended Subsec. (b) by adding definition of “private investment dollars”, effective July 13, 2011.



Agency Legislative Proposal - 2014 Session

Document Name AAC A TECHNICAL CHANGE TO THE Bioscience Innovation Fund

(If submitting an electronically, please label with date, agency, and title of proposal – 092611_SDE_TechRevisions)

State Agency: CONNECTICUT INNOVATIONS
Liaison: LORI GRANATO Phone: 258.7872 © 306.9315 E-mail:
Lead agency division requesting this proposal: CII
Agency Analyst/Drafter of Proposal: LORI GRANATO

Title of Proposal AAC A TECHNICAL CHANGE TO THE Bioscience Innovation Fund
Statutory Reference 32-41aa
Proposal Summary The cost of peer reviews is included in 72(h) and is for outside peer review payment. These payments should not be made out of administrative expenses. Additionally, this proposal allows for the year to year carryover of unused allocations for administrative costs. <i>Please attach a copy of fully drafted bill (required for review)</i>

PROPOSAL BACKGROUND

- Reason for Proposal

Please consider the following, if applicable:

- (1) Have there been changes in federal/state/local laws and regulations that make this legislation necessary?
- (2) Has this proposal or something similar been implemented in other states? If yes, what is the outcome(s)?
- (3) Have certain constituencies called for this action?
- (4) What would happen if this was not enacted in law this session?

- Origin of Proposal New Proposal Resubmission



If this is a resubmission, please share:

- (1) What was the reason this proposal did not pass, or if applicable, was not included in the Administration's package?
- (2) Have there been negotiations/discussions during or after the previous legislative session to improve this proposal?
- (3) Who were the major stakeholders/advocates/legislators involved in the previous work on this legislation?
- (4) What was the last action taken during the past legislative session?

PROPOSAL IMPACT

- **Agencies Affected** (please list for each affected agency)

Agency Name:

Agency Contact (name, title, phone):

Date Contacted:

Approve of Proposal YES NO Talks Ongoing

Summary of Affected Agency's Comments

INTENT OF AMENDED LANGUAGE:

The cost of peer reviews is included in 72(h)and is for outside peer review payment. These payments should not be made out of administrative expenses.

Additionally, this proposal allows for the year to year carryover of unused allocations for administrative costs.

Will there need to be further negotiation? YES NO

- **Fiscal Impact** (please include the proposal section that causes the fiscal impact and the anticipated impact)

Municipal (please include any municipal mandate that can be found within legislation)
NONE

State

Federal
NONE

Additional notes on fiscal impact

- **Policy and Programmatic Impacts** (Please specify the proposal section associated with the impact)



Sec. 70. (NEW) (*Effective from passage*) For the purpose of this section and sections 71 to 73, inclusive, of this act:

(1) "Administrative costs" means the costs paid or incurred by the administrator, including, but not limited to, **[peer review]**, professional fees, allocated staff costs and other out-of-pocket costs attributable to the administration and operation of the Connecticut Bioscience Innovation Fund.

(2) "Administrator" means Connecticut Innovations, Incorporated, in its capacity as administrator of the Connecticut Bioscience Innovation Fund established pursuant to section 72 of this act.

(3) "Advisory committee" means the Bioscience Innovation Advisory Committee established pursuant to section 71 of this act.

(4) "Early-stage business" means a business that has been in operation for not more than three years and is developing or testing a product or service that is (A) not yet available for commercial release, or (B) commercially available in a limited manner, including, but not limited to, market testing of prototypes and clinical trials.

(5) "Eligible recipient" means a duly accredited college or university, a nonprofit corporation or a for-profit start-up or early-stage business.

(6) "Financial assistance" means any and all forms of grants, extensions of credit, loans or loan guarantees, equity investments or other forms of financing.

(7) "Return on investment" means any and all forms of principal or interest payments, guarantee fees, returns on equity investments, royalties, options, warrants and debentures and all other forms of remuneration to the administrator in return for any financial assistance offered or provided.



Sec. 71. (NEW) (*Effective from passage*) (a) There shall be a Bioscience Innovation Advisory Committee that shall consist of the following thirteen members: (1) Four appointed by the Governor; (2) one appointed by the president pro tempore of the Senate; (3) one appointed by the speaker of the House of Representatives; (4) one appointed by the majority leader of the Senate; (5) one appointed by the majority leader of the House of Representatives; (6) one appointed by the minority leader of the Senate; (7) one appointed by the minority leader of the House of Representatives; (8) the Commissioner of Economic and Community Development and the Commissioner of Public Health, or their designees, who shall serve as ex-officio, voting members; and (9) the chief executive officer and executive director of Connecticut Innovations, Incorporated, who shall serve as the chairperson of the advisory committee. Each appointed member shall have skill, knowledge and experience in relevant businesses and sciences related to health care delivery, medical devices, life sciences, insurance or information technology. All initial appointments to the committee pursuant to this subsection shall be made not later than July 1, 2013. Appointed members shall each serve a term that is coterminous with the respective appointing authority. Each member shall hold office until a successor is appointed. Any vacancy occurring on the committee, other than by expiration of term, shall be filled in the same manner as the original appointment for the balance of the unexpired term.

(b) The chairperson shall call the first meeting of the advisory committee not later than September 30, 2013. The advisory committee shall meet not less than quarterly thereafter, and at such other times as the chairperson deems necessary.

(c) No member of the advisory committee shall receive compensation for such member's services, except that each member shall be entitled to reimbursement for actual and necessary expenses incurred during the performance of such member's official duties.

(d) Seven members of the advisory committee shall constitute a quorum for the transaction of any business or the exercise of any power of the advisory committee. The advisory committee may act by a majority of the members present at any meeting at which a quorum is in attendance, for the transaction of any business or the exercise of any power of the advisory committee, except as otherwise provided in this section.



(e) Notwithstanding any provision of the general statutes, it shall not constitute a conflict of interest for a trustee, director, partner, officer, manager, shareholder, proprietor, counsel or employee of an eligible recipient, or any individual with a financial interest in an eligible recipient, to serve as a member of the advisory committee, provided such trustee, director, partner, officer, manager, shareholder, proprietor, counsel, employee or individual shall abstain from deliberation, action or vote by the advisory committee in specific respect to such eligible recipient.

Sec. 72. (NEW) (*Effective from passage*) (a) There is established a Connecticut Bioscience Innovation Fund, to be held, administered, invested and disbursed by the administrator pursuant to this section. The fund shall contain any moneys required or permitted by law to be deposited in the fund and any moneys received from any public or private contributions, gifts, grants, donations, bequests or devises to the fund. Repayment of principal and interest on loans issued from the fund shall be credited to the fund and shall become part of the assets of the fund. Any balance remaining in the fund at the end of any fiscal year shall be carried forward in the fund for the fiscal year next succeeding.

(b) Any return on investment received by the administrator as a result of financial assistance provided from the Connecticut Bioscience Innovation Fund to eligible recipients, or attributable to the investment of the fund by the administrator, shall be deposited and held for the use and benefit of the fund. Moneys in or received for the fund may be deposited with and invested by any institution as may be designated by the administrator at its sole discretion and paid as the administrator shall direct. The administrator may make payments from such deposit accounts for use in accordance with the provisions of this section.

(c) The Connecticut Bioscience Innovation Fund shall not be deemed an account within the General Fund and shall be used exclusively for the purposes provided in this section.

(d) The Connecticut Bioscience Innovation Fund shall be used (1) to provide financial assistance to eligible recipients as may be approved by the advisory committee pursuant to subsection (e) of this section, (2) for the repayment of state bonds in such amounts as may be required by the State Bond Commission, and (3) to pay or reimburse the administrator for administrative costs pursuant to subsection (j) of this section. Such



financial assistance shall be awarded to further the development of bioscience, biomedical engineering, health information management, medical care, medical devices, medical diagnostics, pharmaceuticals, personalized medicine and other related disciplines that are likely to lead to an improvement in or development of services, therapeutics, diagnostics or devices that are commercializable and designed to advance the coordination, quality or efficiency of health care and lower health care costs, and that promise, directly or indirectly, to lead to job growth in the state in these or related fields.

(e) All expenditures from the Connecticut Bioscience Innovation Fund, except for administrative costs reimbursed to the administrator pursuant to subsection (j) of this section and amounts required for the repayment of state bonds in such amounts as may be required by the State Bond Commission, shall be approved by the advisory committee. Any such approval shall be (1) specific to an individual expenditure to be made, (2) for budgeted expenditures with such variations as the advisory committee may authorize at the time of such budget approval, or (3) for a financial assistance program to be administered by staff of the administrator, subject to limits, eligibility requirements and other conditions established by the advisory committee at the time of such program approval.

(f) Connecticut Innovations, Incorporated shall provide any necessary staff, office space, office systems and administrative support for the operation of the Connecticut Bioscience Innovation Fund in accordance with this section. In acting as administrator of the fund, the administrator shall have and may exercise all of the powers of Connecticut Innovations, Incorporated set forth in section 32-39 of the general statutes, provided expenditures from the fund shall be approved by the advisory committee pursuant to subsection (e) of this section.

(g) The advisory committee shall establish an application and approval process with guidelines and terms for financial assistance awarded from the Connecticut Bioscience Innovation Fund to eligible recipients. Such guidelines and terms shall include (1) a requirement that any applicant for financial assistance shall be operating in the state, or proposing to relocate operations to the state, in whole or in part, as a condition of such financial assistance, (2) limitations on the total amount of financial assistance that may be awarded in the form of loans and grants, (3) eligibility requirements for loans and grants designed to encourage and support collaborative ventures among eligible



recipients, (4) peer review requirements, (5) a process for preliminary review of applications for strength and eligibility by the administrator before such applications are presented to the advisory committee for consideration, (6) return on investment objectives, and (7) such other guidelines and terms as the advisory committee determines to be necessary and appropriate in furtherance of the objectives of this section.

(h) Financial assistance awarded from the Connecticut Bioscience Innovation Fund to eligible recipients shall be used for costs related to facilities, necessary furniture, fixtures and equipment, materials and supplies, peer review, **including in connection with application review**, proof of concept or relevance, compensation, **closing costs**, and such other costs that the advisory committee determines to be eligible for financial assistance within the purposes of this section.

(i) Beginning January 1, 2014, the administrator shall prepare for each fiscal year a plan of operations and an operating and capital budget for the Connecticut Bioscience Innovation Fund. Not later than ninety days prior to the start of the fiscal year, the administrator shall submit the plan and budget to the advisory committee for its review and approval.

Subsection (j) of section 72 of public act 13-239 is repealed and the following is substituted in lieu thereof (Effective from passage):

(j) Administrative costs shall be paid or reimbursed to the administrator from the Connecticut Bioscience Innovation Fund, provided the total of such administrative costs **so paid or reimbursed** in any fiscal year shall not exceed five per cent of the total amount of the allotted funding for such fiscal year as determined in the operating budget prepared pursuant to subsection (i) of this section. **If and to the extent the administrator advances administrative costs in any fiscal year in excess of the amount permitted to be reimbursed in such fiscal year, the administrator may carry forward the unreimbursed portion as administrative costs eligible for reimbursement within the permitted limit in a subsequent fiscal year.** Nothing in sections 70 and 71 of this act and this section shall require the administrator to risk or expend the funds of Connecticut Innovations, Incorporated in connection with the administration of the Connecticut Bioscience Innovation Fund.



Agency Legislative Proposal - 2014 Session

Document Name AAC CHANGES TO THE ANGEL TAX CREDIT STATUTES

(If submitting an electronically, please label with date, agency, and title of proposal – 092611_SDE_TechRevisions)

State Agency: CONNECTICUT INNOVATIONS

Liaison: Lori Granato

Phone: 860 258 7872

E-mail: Lori.granato@ctinnovations.com

Lead agency division requesting this proposal: Connecticut Innovations

Agency Analyst/Drafter of Proposal: Lori Granato

Title of Proposal AAC Changes to Angel Tax Credits

Statutory Reference 12-704(d)

Proposal Summary

TO EFFECT NEEDED CHANGES TO THE EXISTING STATUTES TO MAKE PROGRAMS MORE EFFICIENT
Draft form

Please attach a copy of fully drafted bill (required for review)

PROPOSAL BACKGROUND

- **Reason for Proposal**

Please consider the following, if applicable:

- (1) *Have there been changes in federal/state/local laws and regulations that make this legislation necessary?*
- (2) *Has this proposal or something similar been implemented in other states? If yes, what is the outcome(s)?*
- (3) *Have certain constituencies called for this action?*
- (4) *What would happen if this was not enacted in law this session?*

- **Origin of Proposal** New Proposal Resubmission

If this is a resubmission, please share:

- (1) *What was the reason this proposal did not pass, or if applicable, was not included in the Administration's package?*
- (2) *Have there been negotiations/discussions during or after the previous legislative session to improve this proposal?*
- (3) *Who were the major stakeholders/advocates/legislators involved in the previous work on this legislation?*
- (4) *What was the last action taken during the past legislative session?*



Sec. 12-704d. Credits for angel investors. (a) As used in this section:

(1) “Angel investor” means an accredited investor, as defined by the Securities and Exchange Commission, or network of accredited investors who review new or proposed businesses for potential investment who may seek active involvement, such as consulting and mentoring, in a Connecticut business, but “angel investor” does not include (A) a person controlling fifty per cent or more of the Connecticut business invested in by the angel investor, (B) a venture capital company, or (C) any bank, bank and trust company, insurance company, trust company, national bank, savings association or building and loan association for activities that are a part of its normal course of business;

(2) “Cash investment” means the contribution of cash, at a risk of loss, to a qualified Connecticut business in exchange for qualified securities;

(3) “Connecticut business” means any business with its principal place of business in Connecticut that is engaged in bioscience, advanced materials, photonics, information technology, clean technology or any other emerging technology as determined by the Commissioner of Economic and Community Development;

equipment or medical devices and analytical laboratory instruments, operating medical or diagnostic testing laboratories, or conducting pure research and development in life sciences;

(5) “Advanced materials” means developing, formulating or manufacturing advanced alloys, coatings, lubricants, refrigerants, surfactants, emulsifiers or substrates; **ADD ADVANCED MANUFACTURING DESCRIPTION – no description of advanced manufacturing either in CT nor Mass – Jamie – LMK how you would like to proceed**

(6) “Photonics” means generation, emission, transmission, modulation, signal processing, switching, amplification, detection and sensing of light from ultraviolet to infrared and the manufacture, research or development of opto-electronic devices, including, but not limited to, lasers, masers, fiber optic devices, quantum devices, holographic devices and related technologies;

(7) “Information technology” means software publishing, motion picture and video production, teleproduction and postproduction services, telecommunications, data processing, hosting and related services, custom computer programming services, computer system design, computer facilities management services, other computer related services and computer training;



(8) “Clean technology” means the production, manufacture, design, research or development of clean energy, green buildings, smart grid, high-efficiency transportation vehicles and alternative fuels, environmental products, environmental remediation and pollution prevention; and

(9) “Qualified securities” means any form of equity, including a general or limited partnership interest, convertible debt, common stock, preferred stock, with or without voting rights, without regard to seniority position that must be convertible into common stock.

(b) There shall be allowed a credit against the tax imposed under this chapter, other than the liability imposed by section 12-707, for a cash investment of not less than twenty-five thousand dollars in the qualified securities of a Connecticut business by an angel investor. The credit shall be in an amount equal to twenty-five per cent of such investor’s cash investment, provided the total tax credits allowed to any angel investor shall not exceed **[two hundred fifty] five hundred** thousand dollars. The credit shall be claimed in the taxable year in which such cash investment is made by the angel investor and shall not be transferable.

(c) To qualify for a tax credit pursuant to this section, a cash investment shall be in a Connecticut business that (1) has been approved as a qualified Connecticut business pursuant to subsection (d) of this section; (2) had annual gross revenues of less than one million dollars in the most recent income year of such business; (3) has fewer than twenty-five employees,) if such business has employees then not less than seventy-five per cent of its employees working in Connecticut; or is a founding member (4) has been operating in this state for less than seven consecutive years; (5) is primarily owned by the management of the business and their families; and (6) received less than **[two] three** million dollars in cash investments eligible for the tax credits provided by this section. (d) (1) A Connecticut business may apply to Connecticut Innovations, Incorporated, for approval as a Connecticut business qualified to receive cash investments eligible for a tax credit pursuant to this section. The application shall include (A) the name of the business and a copy of the organizational documents of such business, (B) a business plan, including a description of the business and the management, product, market and financial plan of the business, (C) a description of the business’s innovative technology, product or service, (D) a statement of the potential economic impact of the business, including the number, location and types of jobs expected to be created, (E) a description of the qualified securities to be issued and the amount of cash investment sought by the qualified Connecticut business, (F) a statement of the amount, timing and projected



use of the proceeds to be raised from the proposed sale of qualified securities, and (G) such other information as the **[executive director]** Chief executive officer of Connecticut Innovations, Incorporated, may require.

(2) Said **[executive director]**Chief executive officer shall, on or before August 1, 2010, and monthly thereafter, compile a list of approved applications, categorized by the cash investments being sought by the qualified Connecticut business and type of qualified securities offered.

(e) (1) Any angel investor that intends to make a cash investment in a business on such list may apply to Connecticut Innovations, Incorporated, to reserve a tax credit in the amount indicated by such investor. The aggregate amount of all tax credits under this section that may be reserved by Connecticut Innovations, Incorporated, shall not exceed **[six]** ten million dollars annually for the fiscal years commencing July 1, **[2010]** 2014, to July 1, **[2012]**, 2019 inclusive. Connecticut Innovations Incorporated, shall not reserve tax credits under this section for any investment made on or after July 1, **[2014]. 2019** **Statutes do not allow for rolling over of credits. If we could roll unused credits into the next year we would be able to ask for 20 million not 50 million. Will work with DRS for the correct language etc.**

(2) The amount of the credit allowed to any investor pursuant to this section shall not exceed the amount of tax due from such investor under this chapter, other than section 12-707, with respect to such taxable year. Any tax credit that is claimed by the angel investor but not applied against the tax due under this chapter, other than the liability imposed under section 12-707, may be carried forward for the five immediately succeeding taxable years until the full credit has been applied.

(f) If the angel investor is an S corporation or an entity treated as a partnership for federal income tax purposes, the tax credit may be claimed by the shareholders or partners of the angel investor. If the angel investor is a single member limited liability company that is disregarded as an entity separate from its owner, the tax credit may be claimed by such limited liability company's owner, provided such owner is a person subject to the tax imposed under this chapter.

(g) A review of the effectiveness of the credit under this section shall be conducted by Connecticut Innovations, Incorporated, by July 1, 2014. Such review shall be submitted to the joint standing committee of the General Assembly having cognizance of matters relating to commerce.

(P.A. 10-75, S. 15; P.A. 11-254, S. 1; Oct. Sp. Sess. P.A. 11-1, S. 29.)



History: P.A. 10-75 effective July 1, 2010, and applicable to taxable years commencing on or after January 1, 2010; P.A. 11-254 amended Subsec. (d)(1)(C) to delete “and proprietary” re description of business’s technology, product of service, effective July 1, 2011, and applicable to taxable years commencing on or after January 1, 2011; Oct. Sp. Sess. P.A. 11-1 amended Subsec. (b) to lower minimum investment required from \$100,000 to \$25,000, effective October 27, 2011.



Agency Legislative Proposal - 2014 Session

Document Name: **AAC CHANGES TO CII'S bio facilities fund**

(If submitting an electronically, please label with date, agency, and title of proposal – 092611_SDE_TechRevisions)

State Agency: CONNECTICUT INNOVATIONS

Liaison: LORI GRANATO

Phone: 258.7872 © 306.9315

E-mail: Lori.granato@ctinnovations.com

Lead agency division requesting this proposal: CII

Agency Analyst/Drafter of Proposal: LORI GRANATO

Title of Proposal **AAC CHANGES TO CIIS BIOFACILITIES FUND**

Statutory

Proposal Summary

The BioScience Facilities Fund helps qualified firms build out wet laboratory and related space to propel Connecticut's bioscience industry. Since its inception in 1998, the program has committed more than \$37M translating into over 350,000 sq.ft. of lab and support space throughout the state, including 10,600 sq.ft. of transitional wet laboratory space in New Haven's Science Park at Yale. Bioscience entrepreneurs benefit from CI's expertise while their ideas are still conceptual. From there, opportunities exist to obtain needed capital for start-up, expansion and facility fit out.

This fund enables biotechnology and other technology companies to make leasehold improvements to production, testing, research, development, manufacturing, laboratory, and other related facilities. This fund would further enable CI to help the technology companies and provide additional support to them.

With additional focus by the state in the biotechnology arena – this is a natural progression. The companies that the state is currently helping or planning on helping will need additional funding for the next phase of their development. This fund would provide that next stage.

With additional funds – the state can leverage other monies to help support the growing technology based companies.

We have fully utilized the dollars in the fund. This is a popular CII funding vehicle



especially since the state is supporting the bio innovation initiative. This will help bring companies from incubation to seed and to bring in more jobs and federal dollars.

Therefore we are respectfully requesting for 20 million to replenish funds.

Please attach a copy of fully drafted bill (required for review)

PROPOSAL BACKGROUND

- **Reason for Proposal**

Please consider the following, if applicable:

- (1) *Have there been changes in federal/state/local laws and regulations that make this legislation necessary?*
- (2) *Has this proposal or something similar been implemented in other states? If yes, what is the outcome(s)?*
- (3) *Have certain constituencies called for this action?*
- (4) *What would happen if this was not enacted in law this session?*

- **Origin of Proposal** **New Proposal** **Resubmission**

If this is a resubmission, please share:

- (1) *What was the reason this proposal did not pass, or if applicable, was not included in the Administration's package?*
- (2) *Have there been negotiations/discussions during or after the previous legislative session to improve this proposal?*
- (3) *Who were the major stakeholders/advocates/legislators involved in the previous work on this legislation?*
- (4) *What was the last action taken during the past legislative session?*

PROPOSAL IMPACT

- **Agencies Affected** (please list for each affected agency)

Agency Name:

Agency Contact (name, title, phone):

Date Contacted:

Approve of Proposal YES NO Talks Ongoing

Will there need to be further negotiation? YES NO

- **Fiscal Impact** (please include the proposal section that causes the fiscal impact and the anticipated impact)